What is the Difference Between RRMS and PPMS?

🆚 Go to Comparative Table 🆚

Relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS) are two different types of multiple sclerosis (MS), a condition caused by inflammation and immune system attacks on myelin and nerve fibers. The key differences between RRMS and PPMS include:

  1. Diagnosis: RRMS is typically diagnosed earlier in life, while PPMS is diagnosed later, usually in the 40s and 50s.
  2. Symptom progression: People with RRMS experience periods of flare-ups and remission, while those with PPMS are in a continual phase of deterioration.
  3. Lesion distribution: RRMS patients tend to have more brain lesions with more inflammatory cells, while those with PPMS have more spinal cord lesions and fewer inflammatory cells.
  4. Gender prevalence: RRMS affects females two to three times more often than males, while PPMS affects males and females equally.
  5. Mobility issues: People with RRMS will likely have mobility issues, but these issues are more gradual. People with PPMS often experience more mobility issues and have more trouble walking.
  6. Treatment: Ocrevus (ocrelizumab) is the only medication currently approved for PPMS, while RRMS has several treatment options. Research and clinical trials are ongoing to find more treatments specifically for PPMS.

In summary, RRMS is characterized by periods of flare-ups and remission, with more brain lesions and a higher prevalence in females, while PPMS is characterized by a continuous progression of symptoms, with more spinal cord lesions and equal prevalence between males and females.

Comparative Table: RRMS vs PPMS

Here is a table comparing the differences between Relapsing-Remitting Multiple Sclerosis (RRMS) and Primary Progressive Multiple Sclerosis (PPMS):

Feature Relapsing-Remitting MS (RRMS) Primary Progressive MS (PPMS)
Age of Onset Earlier, usually in the 20s or 30s Later, usually in the 40s or 50s
Symptoms Flare-ups followed by remission periods with improved or completely resolved symptoms Steadily worsening neurologic function without distinct attacks or remissions
Disease Course Most people with RRMS eventually develop Secondary Progressive MS (SPMS) after about 10 years No distinct relapses or exacerbations, neurological functions progressively worsen over time
Inflammation More inflammation is present in RRMS Less inflammation is present in PPMS
MRI Features Focal lesions on T2-weighted images and acute inflammatory lesions with contrast enhancement are more common MRI features of chronic inflammation, such as slowly evolving/expanding lesions (SELs) and leptomeningeal enhancement (LME), and brain and spinal cord atrophy are more common
Treatment Medications like Ocrevus (ocrelizumab) are approved for PPMS treatment Ocrevus (ocrelizumab) is the only medication currently approved by the FDA for PPMS treatment

Please note that these are general differences and individual cases may vary. It is essential to consult with a healthcare professional for personalized information and guidance.